Healthcare products company Johnson & Johnson (J&J) (NYSE:JNJ) confirmed on Thursday that it has completed the acquisition of Yellow Jersey Therapeutics for USD1.25bn.
Through this transaction J&J secures the global rights to NM26, a Phase 2-ready bispecific antibody targeting two pathways in atopic dermatitis.
NM26 targets IL-4R alpha subunit and IL-31, which trigger skin inflammation and itch. Atopic dermatitis is a common inflammatory skin disease causing itching, inflammation and increased risk of infections.
J&J aims to expand its treatment options for atopic dermatitis and other immune-mediated diseases.
Eli Lilly's Omvoh receives US FDA approval
Axcynsis Therapeutics' IND for AT03-65 receives US FDA approval
Innovent Biologics' IBI343 receives Breakthrough Therapy Designation in China
OS Therapies reports positive Phase 2b data for OST-HER2 in lung metastatic osteosarcoma
Johnson & Johnson submits New Drug Application for TAR-200 to treat bladder cancer
GenSight Biologics reports positive five-year results for LUMEVOQ gene therapy in LHON Patients
Futura Medical plc reports positive results from WSD4000 Home User Study
Creo Medical Group plc launches robotic-guided lung ablation procedures in the UK
Sen-Jam Pharmaceutical receives ethics approval for Australian clinical trial of SJP-001
Phase I/II clinical trial of Ariceum Therapeutics' 225Ac-SSO110 gets US FDA approval
Kelker Pharma introduces NUTRILINQ for patients using weight loss drugs
HUTCHMED receives full NMPA approval for ORPATHYS in China for MET exon 14 skipping NSCLC
BioArctic reports FDA acceptance of BLA for for subcutaneous maintenance dosing of Leqembi
Revvity and Element Biosciences partner to enhance neonatal sequencing for IVD testing